Name: Bivalirudin Feature: In patients with elective PCI, the incidence of bleeding can be significantly reduced, and the risk of total clinical outcome decreased by 14%. It does not cause antibody-mediated thrombocytopenia. It is reversibly combined with thrombin, with short half-life, and is not prone to ischemic and hemorrhagic complications. It is mainly excreted through the kidney and can be safely used in patients with renal damage.
Composition: Assay: 99% Appearance: White powder CAS No. 128270-60-0 Packing: 25kg Shelf Life:2 years Storage: Store in cool and dry area Certification:ISO.